Skip to main content
Evanthia Galanis, MD, Oncology, Rochester, MN

EvanthiaGalanisMD

Oncology Rochester, MN

Hematologic Oncology, Neuro-Oncology, Sarcoma

Physician

Dr. Galanis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Galanis' full profile

Already have an account?

  • Office

    200 1st St Sw
    Rochester, MN 55905
    Phone+1 507-284-2511

Education & Training

  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1994 - 1998
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1991 - 1994
  • Athens University School of Medicine
    Athens University School of MedicineD.Sc, 1993
  • University of Athens
    University of AthensClass of 1990

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 1993 - 2024
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Elected Member American Society of Clinical Investigation, 2011
  • Elected Member The American Society for Clinical Investigation, 2011
  • Award of Excellence 13th International Conference on Gene Therapy, 2005
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma  
    Domingo-Musibay E, Allen C, Kurokawa C, Hardcastle JJ, Aderca I, Msaouel P, Bansal A, Jiang H, DeGrado TR, Galanis E, Cancer Gene Ther, 1/14/2014
  • New validated prognostic models and prognostic calculators in patients with low grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NC...  
    Gorlia T, Wenting W, Wang M, Baumert B, Mehta M, Buckner JC, Shaw E, Brown P, Stupp R, Galanis E, Lacombe D, van den, Neuro Oncol, 1/1/2013
  • Specific targeting of human interleukin (il)-13 receptor alpha 2-positive cells with lentiviral vectors displaying il-13  
    Ou W, Marino MP, Suzuki A, Joshi B, Husain SR, Maisner A, Galanis E, Puri RK, Reiser J, Human Gene Therapy Methods, 1/1/2012
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).
    Evanthia Galanis, MD, 2014 American Society of Clinical Oncology Annual Meeting, Chicago, IL, 1/1/2014
  • Gene expression profile of innate immune anti-viral factors in ovarian cancer patients treated with oncolytic measles virus.
    Iankov I, Kurokawa C, Middha S, Aderca I, Allen C, Keeney G, Federspiel M, Maurer M, Atherton P, Kalli K, Hartmann L, Galanis E, Mol Ther, 1/1/2014
  • Modulation of innate immunity with ctla4 blockade in measles virotherapy for glioblastoma.
    Hardcastle J, Feng J, Kurokawa C, Domingo-Musibay E, Allen C, Johnson A, Galanis E, Mol Ther, 1/1/2014
  • Join now to see all

Lectures

  • Integrating Tumor Genomics Including WHO Guidelines Into Novel Clinical Trial Designs 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • "Measles and Vesicular Stomatitis Virus Strains as Novel Oncolytic Platforms" 
    Barcleona, Spain - 1/1/2014
  • "Cooperative Group Update" 
    Miami, FL - 1/1/2014
  • Join now to see all

Press Mentions

  • Cancer Cooperative Group Leaders Propose a Re-Engineering of the Nation’s Correlative Science Program for Cancer
    Cancer Cooperative Group Leaders Propose a Re-Engineering of the Nation’s Correlative Science Program for CancerSeptember 18th, 2024
  • Harnessing a Virus to Fight a Killer Brain Tumor in Kids
    Harnessing a Virus to Fight a Killer Brain Tumor in KidsJune 30th, 2022
  • AstraZeneca's Lynparza Fails Phase II, Single-Arm Study in IDH-Mutant High-Grade Glioma
    AstraZeneca's Lynparza Fails Phase II, Single-Arm Study in IDH-Mutant High-Grade GliomaJune 8th, 2021
  • Join now to see all

Professional Memberships